Table 2.
Drug resistance and mutations of the newly reported HIV infections in this study.
| Antiretroviral Drug | Number | % (N1 = 3,596) | HIV Drug Resistance Mutations (n, %) |
|---|---|---|---|
| Total | 303 | 8.4 | |
| PIs | 101 | 2.8 | Q58E (67, 1.9), M46I/L (20, 0.6), L10F (3, 0.1), N88S (2, 0.1), K20T (2, 0.1), T74P (2, 0.1), others (6, 0.2) |
| ATV/r | 4 | 0.1 | |
| FPV/r | 6 | 0.2 | |
| IDV/r | 5 | 0.1 | |
| LPV/r | 3 | 0.1 | |
| NFV | 33 | 0.9 | |
| SQV/r | 4 | 0.1 | |
| TPV/r | 65 | 1.8 | |
| Drug resistance ≥3 | 5 | 0.1 | |
| NRTIs | 49 | 1.4 | M184I/V (17, 0.5), T215A/D/N/S/I (10, 0.3), M41L (6, 0.2), D67N/G (7, 0.2), K65R/N (4, 0.1), K70R/T/N (5, 0.1), L210W (2, 0.1), others (2, 0.1) |
| ABC | 24 | 0.7 | |
| AZT | 17 | 0.5 | |
| D4T | 30 | 0.8 | |
| DDI | 14 | 0.4 | |
| FTC | 21 | 0.6 | |
| 3TC | 21 | 0.6 | |
| TDF | 8 | 0.2 | |
| Drug resistance ≥3 | 26 | 0.7 | |
| NNRTIs | 170 | 4.7 | K103N/R/S (62, 1.7), E138A/G/K (55, 1.5), V179I/L/D (26, 0.7), V106I/M (16, 0.4), K101E/Q (13, 0.4), G190E/A/S (10, 0.3), A98G (6, 0.2), V108I (4, 0.1), others (4, 0.1) |
| DOR | 38 | 1.1 | |
| EFV | 121 | 3.4 | |
| ETR | 38 | 1.1 | |
| NVP | 127 | 3.5 | |
| RPV | 101 | 2.8 | |
| Drug resistance ≥3 | 69 | 1.9 |